***Title:*** Comparison of high intensity interval training versus moderate intensity continuous training in pulmonary rehabilitation for interstitial lung disease; a randomised controlled pilot feasibility trial.

***Authors:***

Dr Dimitra Nikoletou1, 2, PhD dinikole@sgul.ac.uk

Dr Irina Chis-Ster3, PhD ichisste@sgul.ac.uk

Ms Carmen Y. Lech3, BSc carmenyanina.lech@gmail.com

Mr Iain S. MacNaughton3, BSc iainmacn62@gmail.com

Dr Felix Chua MD4, PhD F.Chua@rbht.nhs.uk

Dr Raminder Aul MD5 raminder.aul@stgeorges.nhs.uk

Professor Paul Jones3 MD, PhD pjones@sgul.ac.uk

***Authors’ affiliations:***

1. Centre for Allied Health, Institute of Medical and Biomedical Education, St George’s University of London, Cranmer Terrace, London, SW17 ORE, UK.
2. Faculty of Health, Science, Social care and Education, Kingston University, London, UK.
3. Infection and Immunity Research Institute, St George’s University of London, Cranmer Terrace, London, SW17 ORE, UK
4. Department of Respiratory Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, UK.
5. Department of Respiratory Medicine, St George’s Hospital NHS Foundation Trust, London SW17 ORE, UK

***Corresponding author:***

Dr Dimitra Nikoletou, Centre for Allied Health, St George’s University of London, Cranmer Terrace, London, SW17 ORE and (honorary) Faculty of Health, Science, Social care and Education, Kingston University, London, UK.

Tel: 0208 725 2277 Email: dinikole@sgul.ac.uk

***Key words***: Interstitial lung disease, ILD, Pulmonary rehabilitation, Interstitial pulmonary fibrosis, exercise, high intensity interval training, HIIT.

***Running head***: Feasibility of HIIT versus MICT in ILD PR programmes

***Trial registration:*** This trial was registered in ISRCTN, with the ID number ISRCTN55846300.

***Word count:*** 3949

**Abstract**

**Objectives:** This study aimed to investigate the feasibility and efficacy of high intensity interval training (HIIT) compared to moderate intensity continuous training (MICT) in pulmonary rehabilitation (PR) for people with interstitial lung disease (ILD).

**Design**: Single-centre, randomised controlled feasibility, pilot trial.

**Setting:** Patients were recruited from the chest clinic of a tertiary ILD centre and attended circuit-based PR in the hospital’s gym, followed by a personalised 6-month community programme.

**Participants**: 58 patients, stratified per ILD type, were randomised into two groups: 33 to HIIT (18M: 15F) [mean age (SD) 70.2 (11.4) years] and 25 to the MICT exercise mode (14M: 11F), [mean age (SD) 69.8 (10.8) years].

**Interventions**: 8-week, twice weekly, circuit-based PR programme of exercise and education, followed by a personalised 6-month community exercise programme.

**Outcome measures:** Feasibility outcomes included staff-to-patient ratio and dropout rates per group. Primary outcome was the 6-minute walk distance (6MWD). Secondary outcomes included the sniff nasal pressure, mouth inspiratory and expiratory pressures, handgrip and quadriceps strength and health status. Random-effects models were used to evaluate average variation in outcomes through time across the two groups.

**Results:** The 6MWD peaked earlier with HIIT compared to MICT (at 4 months versus 5 months) but values were lower at peak (mean (95%CI) 26.3m (3.5, 49.1) versus 51.6m (29.2, 73.9) and declined faster at 6-months post PR. Secondary outcomes showed similar faster but smaller improvements with HIIT over MICT and more consistent maintenance 6-months post-PR with MICT than HIIT.

**Conclusions**: HIIT is feasible in circuit-based ILD PR programmes and provides quick improvements but requires closer supervision of training and resources than MICT and benefits may be less well sustained. This would make it a less attractive option for clinical PR programmes. A definitive, multi-centre randomised controlled trial is required to address the role of HIIT in ILD.

**Strengths and Limitations of this study**

* This randomised controlled feasibility, pilot study, showed that HIIT is feasible in circuit-based PR programmes.
* Our results identify the point at which exercise reinforcement may be needed after completion of a HIIT programme.
* Although it was possible to recruit enough ILD patients from a single site, not enough IPF patients could be recruited to evaluate the effect of HIIT on this particular group.
* We did not use supplementary oxygen during PR for patients other than those already on long-term oxygen therapy.
* This study adds valuable information for the design of larger, definitive studies, on the peak and subsequent deterioration of outcomes over time depending on exercise mode.

**Background**

Interstitial lung disease (ILD) is a broad term used to describe a diverse group of pulmonary conditions that cause fibrotic changes in the lung interstitium with subsequent reduction in lung compliance and oxygen diffusion capacity [1, 2]. ILD is categorised into its different types according to clinical, radiological and pathophysiological changes and multidimensional indexes have been created to predict mortality risk [3, 4]. The clinical presentation includes breathlessness on exertion, dry and persistent cough, fatigue, progressive exercise limitation and respiratory failure at the very severe stages. [5] Pharmacological treatment for patients with progressive fibrotic ILD is limited to only a few medications aiming to slow down further development of fibrosis [6] and lung transplantation, the only life-extending option, carries risks and is not available to all patients [7, 8].

Pulmonary rehabilitation (PR) is a non-pharmacological strategy that improves physical function and quality of life [5, 9] but in ILD patients the optimal training programme, especially for longer term benefits, remains unclear. [5, 10] Recent evidence suggests that patients with some types of ILD, such as asbestosis and idiopathic pulmonary fibrosis (IPF), may receive greater benefit from PR than others and effects may be more lasting in patients with milder disease [11]. The traditional exercise mode in PR is moderate intensity continuous training (MICT) which involves continuous exercise for 30-60 minutes at intensities ranging from 60-80% maximum heart rate [12]. However, other training modalities may offer greater benefits.

High intensity interval training (HIIT) is a modality characterised by intervals of high intensity exercise followed by intervals of low intensity or rest [13]. There is growing evidence that HIIT improves a broad range of cardiovascular risk factors, including insulin sensitivity and VO2peak [14], and its safety has been evaluated in patients with cardiovascular and metabolic disease [14-17]. Respiratory patients, who cannot maintain exercise due to breathlessness, have found HIIT acceptable [18- 20] and although its overall superiority over MICT has been questioned [21], it has been used safely in ILD patients preparing for lung transplantation [22]. However, HIIT has yet to be evaluated in the context of an ILD-tailored PR programme.

The aim of this pilot study was therefore to evaluate: a) the feasibility of using HIIT in an ILD-PR programme, b) determine the short and medium-term effects of HIIT on exercise capacity, respiratory and peripheral muscle strength, breathlessness and health status and c) explore responses in different types of ILD.

Some of the results of this study have been reported previously abstract form [23].

**Methods**

**Study design**

Single-blind, randomised-controlled feasibility, pilot trial.

**Study population**

Symptomatic patients over 18 years old, of all types and severity, apart from sarcoidosis, and with a respiratory-physician diagnosis of ILD from a tertiary referral hospital, were invited to participate. This included patients with idiopathic pulmonary fibrosis (diagnostic criteria consistent with the International Consensus statement [1]), connective tissue disease related ILD, non-specific interstitial pneumonia, usual interstitial pneumonia, and chronic hypersensitivity pneumonitis. Patients were eligible to participate if they were ambulant and had symptoms of dyspnoea on exertion (grades 1 to 3 in the mMRC scale) [24]. Patients on long-term oxygen therapy (LTOT) were also included. Exclusion criteria were a history of syncope on exertion, patients having an acute exacerbation, patients with sarcoidosis and severe co-morbidities (such as musculoskeletal, neurological or cardiovascular problems) that would interfere with their ability to exercise.

Prior to being included in this study, all participants had full lung function tests, performed by specialised technicians in a lung function laboratory and CT scans were part of their clinical diagnostic process and management. Participants were monitored throughout the study by respiratory physicians. The usual medical care was not affected by participation in this study.

All participants provided written informed consent. The trial protocol was pre-registered with the ISRCTN registry (ISRCTN55846300) and approved by the South East Coast-Surrey Ethics committee (14/LO/0149).

**Patient and Public involvement**

People with ILD were involved in the original design of this research and determined acceptability of the proposed interventions and likelihood of adherence to this programme. During the study, all participants were involved in the conduct of the research by giving regular feedback in the education-discussion part of the PR programme and via interviews. On completion of this study, some participants formed a local ILD- Support Group and viewed the final results for dissemination.

**Randomisation and blinding**

Following baseline assessments, participants were randomised into 2 groups: exercise using moderate intensity continuous training (MICT group) or exercise using high-intensity interval training (HIIT group). Participants were stratified by ILD type to ensure a balanced distribution of types between groups. They were placed into 3 sub-groups: a) Idiopathic group (e.g. IPF); b) Autoimmune group (CTD-ILD) and c) Chronic Hypersensitivity pneumonitis group (CHP/EAA). The investigator performing all assessments and the statistician were blinded throughout the study.

**Intervention**

*The ILD-PR programme*

This was a circuit-based 8-week, twice weekly, outpatient programme, including only people with ILD and consisting of an hour of exercise and an hour of education. Exercise was set, supervised and progressed by two experienced physiotherapists, according to a standardised protocol for each group allocation. Supplementary oxygen was not used during the sessions. Participants already on LTOT continued to exercise with oxygen as recommended but were not given additional oxygen. Aerobic exercises included treadmill walking, brisk walking between 2 cones, cycle ergometer, trampette and step ups. Strength training exercises, upper and lower limb, were conducted using ‘Thera-bands’ and functional movements such as sit-to-stand and ball raises.

A minimum of 30 minutes were dedicated to aerobic training. Aerobic training intensity at theMICT group was set at 60% maximum heart rate (HRmax) and progressed each week. In theHIIT group, intensity was set at 80% HRmax and patients were instructed to exercise in dynamic intervals followed by low intensity exercise or rest. The aim in this group was to increase the amount of time on the ‘high intensity’ phase each week.

In the first week, the average time on HIIT (at 80% HRmax) for each aerobic exercise was 2.5 min, therefore HIIT was 12.5 minutes of the total 30-minute session, and this time increased each week. Progression of training was determined by reducing time in the low intensity phase of HIIT and/or increasing time in the target HR . Each participant’s individualised programme was recorded on exercise logs during the sessions.

Heart rate and oxygen saturation were monitored using pulse oximeters and perceived exertion and breathlessness were recorded at set intervals using the modified 10-point Borg scale and the Rate of Perceived Exertion scale (RPE) respectively [25, 26].

The education session, on the 2nd hour of the programme was common for all participants and included presentations and discussion on topics important to ILD patients, such as: Topics about breathing and breathlessness (mechanics of breathing, helpful/unhelpful breathing patterns, the Active Cycle of Breathing technique, useful positions for recovering, pacing), topics about ILD (what happens with ILD, cough, associated conditions-rheumatoid Arthritis, Gastro-Oesophageal Reflux disease, Sjӧgren’s syndrome, Bird Fancier’s Lung, Idiopathic Pulmonary Fibrosis) and topics about managing the condition (Why healthier lifestyle is important, keeping good posture, barriers to activity/exercise, dietary advice, smoking, incontinence, relaxation information, mood, anxiety and breathlessness, self-management and goal setting).

On the first day of the programme all participants were given an ‘ILD-Pulmonary rehabilitation booklet’ designed by our team, which contained information and pictures of all exercises, an exercise diary and summary of the education topics (see Supplementary file 1). All participants were encouraged to continue exercising at home on the days they did not attend the programme.

*The 6-month programme*

Following completion of the PR programme, participants were given a personalised exercise programme, starting at the level achieved at the end of PR, and were asked to continue to exercise 3 times per week as well as do daily walking. The plan was recorded in their personal booklet. The 6-month programme included outdoor walking in HIIT or MICT mode, as well as stretching and strength training exercises. Some participants joined their local gym or organised exercise classes to ensure participation in group exercise at least once per week and followed a home programme the remaining time. Others opted for home-based exercise only. Regardless of the choice, during the 6-month period, participants were self-monitoring and had regular phone calls (once per month) and at least one home visit by the research physiotherapists on the 3rd month. The physiotherapists guided participants on filling in the exercise diaries and progressing training depending on mode of exercise. The ILD-PR booklet was used as a resource for the home exercises and as a reminder of the educational topics.

**Outcomes**

All assessments were performed by the same investigator (DN), using identical instructions and methods, at three time points; at baseline, at 8-weeks (post-PR) and at 6 months (post-community programme). The investigator was blinded throughout the study.

Feasibility outcomes included the proportion of eligible patients who consented to the study, attrition in each group, staff-to-patient ratio and supervision requirements, reasons for discontinuing the programme and adverse events.

The primary efficacy outcome was functional exercise capacity and was measured using the 6-minute walk test distance (6MWD) as recommended by the ATS guidelines [27] using standardised instructions.

Secondary outcomes were: a) Respiratory muscle function- Sniff nasal pressure (SNIP) and the maximal inspiratory and expiratory pressures (PImax and PEmax) were recorded using a handheld portable respiratory muscle testing device (MicroRPM, CareFusion, Basingstoke, UK). A minimum of 10 attempts were made for each test, on at least one session. PImax was recorded from functional residual capacity (FRC) and PEmax from total lung capacity (TLC).

b) Peripheral muscle function- Handgrip strength, assessed in the dominant hand, with the elbow at 90 degrees angle, using a hydraulic hand dynamometer (JAMAR Hydraulic Hand Dynamometer, Homecraft Rolyan Ltd, Nottinghamshire, UK). Quadriceps strength (QUADS-DOM) and hip flexion (HIP-DOM) were assessed in sitting position, with the knee at 90 degrees angle and back upright and supported using a hand-held dynamometer (Lafayette Manual Muscle Tester Model 01163, Lafayette Instruments, Lafayette, IN, USA).

c) Health status, using the St George’s Respiratory Questionnaire for IPF (SGRQ-I) [28] and the Hospital Anxiety and Depression scale (HAD) [29].

Spirometry data and anthropometric measurements (height, weight, %fat, waist, hip and neck circumference) were also collected.

Data were collected and managed using REDCap electronic data capture tools hosted at the NHS Trust [30].

**Statistical analysis**

This was a pilot study to test feasibility of the HIIT exercise mode and inform the design and power of a larger, next phase, randomised controlled trial. Intention-to-treat analyses are presented- that is, all participants who were randomised were considered in the analysis, not only those who completed the programme- together with estimates’ uncertainties as 95% CIs. This is not a hypothesis testing setting, hence the numbers followed instructions from the literature [31]. An indicative sample size calculation was based on previous research aiming to detect between-group changes of 38± 43m in the 6MWD following rehabilitation [32-34], with an 80% power and a probability of type 1 error of 0.05.

Exploratory analyses used random effects (mixed) models to estimate average values in outcomes across the follow-up time for the four continuous longitudinal outcomes of interest, i.e., 6MWD, SNIP, SGRQ-I and Quads strength which were relatively normally distributed on each occasion. Average estimates of these measurements were derived following fitting a series of a nonlinear, quadratic mixed models over time allowing for a 3-way interaction between time, intervention (HIIT vs MICT) and clinical group (ILD type) as well as between age, intervention and clinical group. For each of the 4 key exploratory outcomes of interest , a series of nested models of increasing complexity were developed and tested for their statistical improvement against the next less complex model. The complete data analysis (using missing data jargon) using mixed modelling on the 4 continuous longitudinal outcomes accounted for all participants and their complete observations (intention to treat analyses) and operated under ‘missing at random’ assumption for the attrition at the follow-up- assumption which is not testable from the data at hand

 [35]. Although the missing data are less important in such pilot/feasibility settings [31], we did investigate its patterns- particularly to assess potential differences between groups defined by intervention and /or clinical characteristics Longitudinal binary outcomes were defined as 1 for a missing observation and 0 otherwise- at the baseline and at the follow-up and for each outcome- and have been explored using longitudinal models with random effects. The results of these exploratory analyses are presented in Supplementary file 2.

The average variation of outcomes through time, within and between-groups, are presented as means (95% CI) and descriptive statistics as mean (SD). All analyses were conducted on STATA software (version 11).

**Results**

**Patient flow**

60 participants consented to the study but two participants withdrew prior to commencement of the PR programme. A total of 58 started the PR programme. Figure 1 is the CONSORT diagram showing participant flow.

*Figure 1 around here*

Baseline characteristics are shown in Table 1 *.* There were no differences between groups at baseline, except for DLCO which was significantly lower in the HIIT group.

**Table 1**: Baseline characteristics

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **Total Group****(n= 58)** | **Control group****(MICT)****(n=25)** | **Intervention group (HIIT)****(n=33)** | **Between group****P value** |
| **Age (years)** | 70.0 (11.05) | 69.8 (10.8) | 70.5 (10.9) | 0.89 |
| **Gender (male), (number (%))** | 32 (55.2) | 14 (56) | 18 (55) | 0.91 |
| **ILD Type, (no. (%))*** IPF
* CTD-ILD
* CHP
 | 18 (31.0)28 (48.3)12 (20.7) | 8 (32)15 (60)2 (8) | 10 (30.3)13 (39.4)10 (30.3) | 0.10 |
| **ILD-GAP index,**(number (%))* 0-1
* 2-3
* 4-5
* >5
 | 24 (41.4)20 (34.5)10 (17.2)2 (3.4) | 12 (48)9 (36)4 (16)0 (0) | 12 (48)11 (33.3)6 (18.2)2 (6.1) | 0.72§ |
| **BMI (kg/m2)** | 27.3 (4.6) | 27.5 (3.8) | 27.2 (5.1) | 0.84 |
| **Waist/Hip ratio** | 0.9 (0.1) | 0.9 (0.1) | 0.9 (0.1) | 0.60 |
| **Fat (%)** | 29.9 (8.6) | 29.9 (9.3) | 30.1 (8.1) | 0.95 |
| **FVC (%,predicted)** | 79.1 (21.8) | 85.8 (24.0) | 73.8 (18.8) | 0.11 |
| **DLCO (%, predicted)** | 47.0 (14.7) | 53.9 (13.1) | 41.7 (13.9) | 0.002 |
| **Comorbidities (no. (%))*** Cardiac
* Hypertension
* Diabetes
* High Cholesterol
 | 21 (36.2)23 (39.7)15 (25.9)12 (20.7) | 8 (32)9 (36)7 (28)7 (28) | 13 (39.4)14 (42.4)8 (24.2)5 (15.2) | 0.560.620.750.23 |
| **Prednisolone medication****(no. (%))*** < 5mg
* 5-10 mg
* >10 mg
 | 19 (32.8)19 (32.8)3 (5.17) | 9 (36)5 (20)2 (8) | 10 (30.3)14 (42.4)1 (3) | 0.34§ |
| **Smoking status (no. (%))*** Current smoker
* Former smoker
* Never smoked
* Missing records
 | 13 (22.4)9 (15.5)33 (56.9)3 | 5 (20)6 (24)13 (52)1 | 8 (24.2)3 (9.1)20 (60.6)2 | 0.31§ |
| **Pack year history** | 8.9 (15.9) | 10.7 (16.5) | 7.4 (15.6) | 0.50 |
| Median/IQR interval | 0(0, 10) | 0(0, 20) | 0(0, 4.5) |  |
| Missing | 7 | 3 | 5 |  |
| **6MWD (m)** | 371.7 (122.2) | 380.8 (139.8) | 364.6 (108.3) | 0.65 |
| 6MWD Missing | 6 | 2 | 4 |  |
| **SpO2 in room air (%)** | 96 (1.5) | 96.5 (1.8) | 96 (1.5) | 0.3 |
| Missing | 6 | 2 | 4 |  |
| **No. on LTOT**  | 3 | 1 | 2 | n/a |
| **SNIP (cmH2O)** | 94.8 (24.3) | 96.8 (25.9) | 93.1 (24.5) | 0.61 |
| Missing | 9 | 3 | 6 |  |
| **PImax (cmH2O)** | 91.5 (30.4) | 91.1 (34.2) | 91.8 (27.4) |  |
| Missing | 8 | 2 | 6 |  |
| **PEmax (cmH2O)** | 106.6 (32.0) | 114.4 (40.3) | 100.7 (23.5) | 0.22 |
| Missing | 23 | 10 | 13 |  |
| **Handgrip (dominant hand) (kg)** | 25.8 (10.2) | 27.2 (11.2) | 24.8 (9.4) | 0.42 |
| Handgrip Missing | 4 | 2 | 2 |  |
| **Quads extension (dominant side) (kg)** | 18.3 (5.5) | 18.7 (6.2) | 18 (5.0) | 0.65 |
| Missing | 2 | 0 | 2 |  |
| **Hip flexion (dominant side) (kg)** | 15.6 (4.6) | 15.3 (5.1) | 15.9 (4.3) | 0.41 |
| Missing | 1 | 0 | 1 |  |
| **HAD-A** | 6.3 (4.2) | 6.2 (4.6) | 6.3 (3.9) | 0.88 |
| Missing | 1 | 0 | 1 |  |
| **HAD-D** | 5.5 (3.7) | 5.8 (3.2) | 5.2 (4.0) | 0.28 |
| Missing | 1 | 0 | 1 |  |
| **SGRQ-I Total score** | 46.6 (21.2) | 43.3 (20.3) | 49.3 (21.8) | 0.29 |
| Missing | 1 | 0 | 1 |  |

Data are means (SD) unless otherwise stated. The p-value tests the general null hypothesis of similarity between the randomized groups. The methods include t-tests (equal or unequal variances), Kruskal- Wallis and chi-squared (Fisher exact) as appropriate according to the nature of the variables. All tests have been carried out on the complete data only and missing data were not considered as a separate category. §= p value was calculated considering the whole (balanced) distribution.

**Feasibility of HIIT compared to MICT**

HIIT was well tolerated in a circuit-based clinical PR programme but required closer supervision to monitor participants’ target heart rate and avoid desaturation below 85%. There were no adverse events from HIIT during or after the PR programme although attrition in the HIIT group was higher (42% compared to 28% in the MICT group) this did not appear to be due to a specific factor that could be directly attributed to the type of programme (Figure 1).

**Change in exercise capacity, respiratory and peripheral muscle strength and health status**

The change in outcomes from baseline at all assessment points are shown in Figure 2 and suggest a non-linear trend. This was then tested using linear and non-linear models and it was found that a quadratic model provided a significantly better fit than a linear model. The 6MWD increased over time from baseline in both groups, after which it tended to return towards starting levels (p<0.001 for a quadratic term of change over time), Figure 3. The p value for the group-time interaction term was p=0.006 suggesting that the trajectories differed between groups. The HIIT group peaked quicker, around 4 months compared to around 5 months with MICT (Figure 3). The models also suggested that the change in 6MWD values were smaller with HIIT (Table 2, Figure 2); mean change at peak was 51.6m (95% CI 29.2, 73.9) in the MICT group compared to 26.3m (3.5, 49.1) with HIIT. The picture was the same using the estimates at 2 and 8 months (Table 2, Figure 2). Age was inversely associated with the average 6MWD values in both groups, but the time course was similar across ages (Fig. 3).

*Figure 2 and 3 around here*

**Table 2:** Average predictions for main outcomes values at the main time points during the trial and for changes from baseline (actual and adjusted for age)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outcome** | **Time** | **Group data**Mean (95% CI) | **Change** **from baseline**Mean (95% CI) | **Change****from baseline adjusted for age**Mean (95% CI) |
| **Control****(MICT)** | **Intervention****(HIIT)** | **Control****(MICT)** | **Intervention****(HIIT)** | **Control****(MICT)** | **Intervention****(HIIT)** |
|  |  |  |  |  |  |
| **6MWD (m)** | **Baseline** | 382(336, 429**)** | 372(331, 412) |  |  |  |  |
| **2 months** | 433(386 480) | 411(370, 453) | 54.7(32., 76.9) | 38.6(15.95, 61.17) | 53.2(33.66, 72.70) | 36.3(16.42, 56.06) |
| **8 months** | 428(378, 476) | 374(331, 418) | 48.2(24.0, 72.4) | 2.64(-23.4, 28.6) | 46.6(26.5, 66.7) | .06(-21.95, 22.08) |
| **Peak value** | 460(411, 508) | 425(382, 468) | 51.6 (29.2, 73.9) | 26.29(3.5, 49.1) | 50.02(31.2, 68.8) | 23.88(4.5, 43.3) |
| **Peak time-months** | 4.87(4.43, 5.30) | 4.05(3.62, 4.48) |  |  |  |  |
| **SNIP (cmH2O)** | **Baseline** | 95(85, 105) | 92(82, 101) |  |  |  |  |
| **2 months** | 104(94, 115) | 98(88, 108 | 9.53(2.02, 17.04**)** | 10.07(2.28, 17.85) | 9.21(1.98, 16.4) | 9.40(1.88, 16.92) |
| **8 months** | 101(90, 112) | 86.9(76, 98) | 8.08(-0.32, 16.48) | -5.73(-15.03, 3.56) | 7.38-1.05774 15.81 | -6.35-15.64376 2.95 |
| **Peak value** | 108(97, 120) | 99(89, 110) | 8.89(2.33, 15.44) | 6.01(-1.10, 13.12) | 8.39(2.00, 14.78) | 5.36(-1.53, 12.25) |
| **Peak time-months** | 4.57(3.72, 5.43) | 3.54(2.57, 4.51) |  |  |  |  |
| **QUADS DOM (kg)** | **Baseline** | 18.8(16.7, 20.9) | 17.6(15.7, 19.5) |  |  |  |  |
| **2 months** | 21.6(19.4, 23.8) | 20.1(18.1, 22.1) | 3.37(1.97, 4.78) | 2.44(1.09, 3.78) | 3.33(1.91, 4.74) | 2.39(1.03, 3.74) |
| **8 months** | 22.7(20.2, 25.6) | 20.6(18.2, 23.0) | 4.10(2.48, 5.72) | 3.16(1.55, 4.78) | 4.06(2.46, 5.65) | 3.12(1.52, 4.71) |
| **Peak value** | 23.5(21.0, 26.0) | 21.7(19.3, 24.1) | 3.82(2.46, 5.17) | 2.83(1.53, 4.13) | 3.77(2.43, 5.11) | 2.78(1.49, 4.07) |
| **Peak time-months** | 5.65(4.39,6.91) | 5.27(4.19, 6.36) |  |  |  |  |
| **SGRQ-I (Total score)** | **Baseline** | 43.2(35.4, 51.1) | 48.8(41.9, 55.7) |  |  |  |  |
| **2 months** | 36.6(28.5, 44.7) | 43.0(35.8, 50.2)  | -6.57(-11.81, -1.33) | -3.75(-8.92, 1.42) | -6.39(-11.62, -1.17) | -3.54(-8.71, 1.63) |
| **8 months** | 40.3(31.8, 48.8) | 49.2(41.3, 57.1) | -2.57(-8.06, 2.92) | 2.15(-3.39, 7.68) | -2.40(-7.89, 3.09) | 2.37(-3.18, 7.93) |
| **Min value** | 33.9(25.1, 42.6) | 41.1(33.1, 49.1) | -4.99(-9.62, -0.36) | -1.84(-6.51, 2.83) | -4.82(-9.44, -0.19) | -1.63(-6.31, 3.05) |
| **Min time-months** | 4.37(3.68, 5.07) | 3.94(3.24, 4.65) |  |  |  |  |

The quadratic term was significant for all secondary outcomes (p=0.0014 for SNIP, p= 0.004 for QUADS-DOM and p= 0.0014 for SGRQ-I), (Figure 3).

SNIP values peaked earlier than 6MWD values in both groups by approximately 2 weeks (Figure 3). QUADS-DOM values were maintained above baseline levels in both groups (Figure 2) and showed a similar time course of change.

There was no evidence for a difference between treatment groups for the SGRQ-I values. The time to reaching the greatest improvement in SGRQ-I score was shorter in the HIIT group, but the changes in the HIIT group were of smaller magnitude at all time-points (Supplementary Tables 1 and 2).

**Effects of HIIT on different aetiology ILD**

Our models included 3-way interactions between time, intervention (HIIT or MICT) and clinical group, to predict changes from baseline in the combined fibrosis (IPF and CHP group) and CTD-ILD groups. The patterns of change are consistent with the primary analysis – i.e. that whilst the HIIT group peaked faster than the MICT group, the level of improvement was less (Supplementary Tables 1 and 2 and Supplementary Figures 1-4).

**The effect of baseline DLCO on HIIT**

Despite stratified randomisation, DLCO seemed to differ between intervention groups. (Table 1). We therefore performed additional, post-hoc analyses to examine its possible effect on outcomes. Based on these data, there was no evidence to suggest that DLCO further explained differences in the outcomes after accounting for time, age at the recruitment, intervention and clinical groups and their interactions (see Supplementary file 3).

**Discussion**

To our knowledge, this is the first study to investigate the feasibility and potential efficacy of HIIT in the context of a circuit-based clinical PR programme for ILD and compare it with MICT. It demonstrated the feasibility of HIIT, in PR for ILD patients and provided preliminary data on the exercise mode more likely to maintain benefits 6 months after programme completion. In addition, we identified the time of peak benefit and time course of subsequent deterioration.

HIIT proved to be feasible and well tolerated but required closer supervision and careful instructions for patients to continue this mode of training than MICT. The attrition rate was higher in the HIIT group compared to the MICT group and more contact was needed in the 6-month period to ensure the HIIT mode of training met the protocol requirements.

The preliminary efficacy of HIIT over MICT was tested using random effects models. Their aim was to understand the average variation of the four key outcomes through time across groups to answer five main questions: a) How do these measurements change over time?; b) Does the benefit differ between groups?; c) How sustainable is the benefit? d) Does the attrition rate differ between groups? e) What is the influence of age? The study was primarily designed to compare the two treatment groups, but an exploratory analysis was performed to look for differences between clinical groups, although this resulted in small numbers in the subgroups.

Contrary to our initial hypothesis, our data showed no evidence of greater benefit with HIIT compared to that achieved with MICT in exercise capacity, respiratory and peripheral muscle function or health status in the medium-term. The study was designed as a pilot to test the potential for a trial of HIIT in a larger, definitive study, but we are forced to conclude that a study of the same design may not be worthwhile.

At 2 months, both groups improved > 34 meters in the 6MWD, which is the reported minimal clinical important difference (MCID) in IPF patients [32, 36, 37], adding to existing evidence on the benefits of PR in ILD [11, 32-33, 38-42]. However, although the 6MWD improved earlier in the HIIT group (peaking at 4 months instead of 5 months) differences from baseline were consistently lower and not as well maintained at 8 months compared with the MICT group. A similar pattern emerged when the effect of age was added to the model. Age is an important factor in indices associated with mortality risk in ILD [3, 4] and our results showed lower 6MWD with greater age. Despite this age effect, PR had a positive effect in all age groups regardless of baseline levels, contrary to previous studies reporting greater improvement in patients with lower baseline 6MWD [11, 37, 41, 43]. However, HIIT did not offer additional or preferential benefits to any specific age group and tended to decline below baseline levels at 8 months in the older group. In contrast, the benefit seen in the older MICT group was maintained above baseline levels.

In addition to functional exercise capacity, patients improved quadriceps muscle strength post-PR but similarly, there was no difference between treatment groups. Age-adjusted results for quadriceps force were less variable than for 6MWD and benefits were well maintained above baseline in both groups. The modelling suggested that quadriceps force peaked a little later than other outcomes at 5.5 months in the MICT group and at 5 months at the HIIT group. Our results support the inclusion of strength training in ILD-PR programmes and suggest that it may explain why some studies showed greater improvement and maintenance in functional capacity [33] while others that focused on endurance training did not [11]. The time course of peak improvement and subsequent decline in quadriceps strength did not follow the pattern seen with 6MWD, in either group. Quadriceps strength has been shown to deteriorate in line with ageing and severity in other chronic respiratory disorders [44] and has been identified as an important predictor of mortality in COPD [45]. Skeletal muscle atrophy has also been identified in advanced ILD [46]. Our ILD group, which included people in advanced stage (as defined by the ILD-GAP score > 5, Table 1) showed improvement in mean quadriceps force post-PR in both groups and across all age groups. We found no evidence that older individuals benefited more from PR.

Respiratory muscle strength was preserved at baseline (mean SNIP, MIP and MEP > 70 cmH2O in both groups) as previous described [47, 48] and improved post-PR in both groups even though there was no inclusion of specific inspiratory muscle training in our programme. In addition, the SNIP followed a similar pattern over time to 6MWD and peaked approximately two weeks earlier than the 6MWD in both the HIIT and MICT group. Although there was no additional benefit with HIIT, our results suggest that SNIP may be more useful in monitoring changes following PR than quadriceps force in ILD patients. In support of this conclusion, Mendoza and colleagues [47] showed that inspiratory muscle strength correlated better with 6MWD than quadriceps twitch force in patients with fibrotic idiopathic interstitial pneumonia. Although our ILD group was more mixed and included CTD-ILD patients, our results confirm that respiratory muscle strength appears preserved in ILD and that inspiratory muscle strength correlates well with the 6MWD. Our study is the first to show that inspiratory muscle strength changes in tandem with the 6MWD following PR, regardless of the chosen mode of training.

Health status, as defined by the SGRQ-I and HAD scale improved post-PR and was maintained at 8 months, but again, there was no evidence of superiority of HIIT over the MICT group (Table 1- online supplement).

*Effects of HIIT on different aetiology ILD*

Random effect models were also created based on ILD type (clinical subgroups). We combined the IPF and CHP subgroups into the combined ‘Fibrosis’ clinical group. This was due to smaller numbers of IPF participants at the end of the study which did not allow for independent evaluation of this subgroup.

The effects of HIIT on ILD of different aetiology were consistent with our primary analysis, i.e. that HIIT peaked faster and the level of improvement was less. This result seemed to be largely attributable to the fibrosis group, which peaked fastest but showed the lowest improvement from baseline compared to the CTD-ILD group. Similar findings were observed for the other outcomes, again showing lack of preferential benefit from HIIT in any subgroup. Whilst the CTD-ILD subgroup improved in most variables, the HIIT mode was not superior to MICT.

*Limitations*

The study has limitations. First, although our retrospective analysis showed no evidence that baseline DLCO had an effect on outcomes following our training programme (Supplementary file 3), the effect may have been concealed by the size of this pilot study. Imbalance in randomisation can happen by chance in clinical trial settings, particularly in pilot/feasibility studies [49]. However, DLCO did not affect PR benefits in a previous study [50], but future definitive studies may need to consider controlling this factor at randomisation.

Second, we did not use supplementary oxygen during PR for participants other than for those already on long term oxygen therapy (LTOT). Although promising benefits have been reported with acute oxygen supplementation during exercise in IPF patients [51], there is still insufficient evidence about medium to long-term benefits in ILD patients [34] For our study, we felt it was important to train participants to recognise the time it took before desaturation occurred, so that they were able to continue that pattern of training and monitor themselves when unsupervised in community. Participants already on LTOT continued to exercise with oxygen. However, none of the three participants on LTOT finished PR, regardless of group allocation, supporting previous reports that PR may not be appropriate for them [52]. Future studies need to explore different models of training for these cases, such as home-based programmes.

Finally, the number of IPF participants who remained in the study was small and did not allow us to investigate the effect of HIIT over time in this particular group.

*Implications for future definitive studies*

This pilot, enabled us to explore the effect of mode of training on an ILD-PR programme of 8-weeks duration followed by community-based training for 6 months. Our programme duration reflects current UK-based clinical programmes and showed improvements that were maintained at 8 months and were similar to a recent study of a much longer PR programme duration [33]. Although we conclude that there is no evidence to support the use of HIIT in a future definitive study of similar design to this pilot, our results suggest that HIIT may have a role when quicker improvements are required, such as in pre-operative rehabilitation for ILD and that HIIT is feasible to be investigated further in a larger, definitive study of different design. Our results also provide valuable information on the time point where 6MWD and other variables start to deteriorate post-PR and therefore, an estimate of time when additional PR support may be needed, thus optimising PR provision for ILD patients.

**Conclusions**

In the current study, HIIT was found to be feasible and improved exercise capacity in an ILD-PR programme, but this exercise modality showed no evidence of superiority over MICT.Indeed, our findings suggest that it may be less effective and may require closer monitoring to avoid exercise-induced desaturation so, until further evidence becomes available, MICT appears to be more appropriate in the general clinical setting.

***Author Contributions:*** Concept and Design of Study: DN, PJ, FC, RA, IC-S; Acquisition of Data: DN, CL, IMcN ; Statistical Analytical Strategy: ICS, Analysis of Data: DN, IC-S; Drafting of Manuscript: DN, IC-S, PJ ; Revision of manuscript critically for important intellectual content: All authors; Approval of final manuscript: All authors

***Competing interests***: In the last 36 months:

DN, IMN and CYL declare no financial interests.

ICS- has had grants from NIHR, Astra-Zeneca and BHF and is a statistical expert for the Health Research Authority

FC- has received speaker fees and financial sponsorship for conducting meetings by Boehringer-Ingelheim and Roche

RA- has received lecture fees from Pfizer and Novartis

PJ- owns GlaxoSmithKline shares

***Ethics statement:*** Ethical approval was secured through the South East Coast-Surrey NRES committee (REC reference: 14/LO/0149) on the 14th February 2014.

***Funding statement:*** The study was funded by the National Institute for Health Research (NIHR) Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-1112-29067). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

***Study registration and timeline:*** The trial protocol was pre-registered with the ISRCTN registry (ISRCTN55846300). Study duration: 02/05/2014 to 30/09/2016 (last participant assessment), Analysis completed: 2017.

***Data sharing statement:*** Data are available upon reasonable request. All relevant data are presented in this paper; and more information can be provided upon reasonable request from the corresponding author

**Acknowledgements:** The authors would like to thank all ILD patients and particularly the St George’s Interstitial Lung Disease Support Group for their participation and input in this study.

**List of figures:**

**Figure 1:** CONSORT diagram of participants’ flow in the study. ILD-PR= pulmonary rehabilitation programme tailored for interstitial lung disease patients, MICT= moderate intensity continuous training, HIIT= high intensity interval training, IPF= idiopathic pulmonary fibrosis, CTD-ILD= connective tissue disease related interstitial lung disease, CHP= chronic hypersensitivity pneumonitis.

**Figure 2:** Change from baseline in 4 key outcomes by intervention group over time.

**Figure 3:** Age-related variations in the 4 key outcomes (6MWD, SNIP, QUADS-DOM (Quadriceps strength) and SGRQ-I total score) per training group using random effects models. The vertical line indicates the inflection point (i.e. highest or lowest values) in each age group. The ages are the mean values in each tertile

**Supplementary Figure 1**: Changes in key outcomes by intervention and ILD clinical groups

**Supplementary Figure 2**: Random effects models for the 6MWD by intervention (HIIT vs MICT) and ILD clinical subgroup (Fibrosis vs CTD-ILD)

**Supplementary Figure 3**: Random effects models for SNIP by intervention (HIIT vs MICT) and ILD clinical subgroup (Fibrosis vs CTD-ILD)

**Supplementary Figure 4**: Random effects models for quadriceps strength-dominant side (Quad\_dom) by MICT vs HIIT and ILD clinical subgroups.

**References**

1. Travis WD, Costabel U, Hansell DM, et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2013 Sep 15; 188 (6): 733-48.
2. Wells AU and Hirani N. BTS Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. *Thorax* 2008; 63 (Suppl V): v1- v58.
3. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern Med.* 2012; 156 (10): 684-91.
4. Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic Interstitial Lung Disease- The ILD-GAP model. *Chest* 2014; 145 (4): 723-28.
5. Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. *Cochrane Database Syst Rev.* 2021 J; 2 (2):CD006322.
6. Cottin V, Wollin L, Fisher A, et al. Fibrosing interstitial lung diseases: knowns and unknowns. *Eur Respir Rev* 2019; 28: 180100 [https://doi.org/10.1183/16000617.0100-2018].
7. Leong S W, Bos S, Lordan J L, et al. Lung transplantation for interstitial lung disease: evolution over three decades. *BMJ Open Resp Res* 2023; 10: e001387. doi:10.1136/bmjresp-2022-001387.
8. Kapnadak SG, Raghu G. Lung transplantation for interstitial lung disease. *Eur Respir Rev* 2021; 30: 210017 [DOI: 10.1183/16000617.0017-2021]
9. Spruit M. A., Singh S., Garvey C, et al. An Official American Thoracic Society/European Respiratory Society statement: Key concepts and advances in Pulmonary Rehabilitation. *Am J Resp Crit Care Med* 2013; Vol 188 (no 8): e13-e64.
10. Holland AE, Hill CJ, Conron M, *et al*. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. *Thorax* 2008; 63: 549-554.
11. Dowman L. M, McDonald C.F., Hill C.J, *et al.* The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. *Thorax* 2017; 0: 1-10.
12. American College of Sports Medicine (ACSM)Guidelines for exercise testing and prescription. (2022) 11th edition. Wolters Kluwer Health
13. Helgerud J, Høydal K, Wang E, Karlsen T, Berg P, Bjerkaas M, et al. Aerobic high-intensity intervals improve VO2max more than moderate training. *Med Sci Sports Exerc* 2007; 39 (4):665–71.
14. Levinger et al. What Doesn’t Kill You Makes You Fitter: A Systematic Review of High-Intensity Interval Exercise for Patients with Cardiovascular and Metabolic Diseases. *Clinical Medicine Insights: Cardiology* 2015:9 53–63.
15. Arena R, Myers J, Forman DE, Lavie CJ, Guazzi M. Should high-intensity-aerobic interval training become the clinical standard in heart failure? *Heart Fail Rev*. 2013; 18 (1): 95–105.
16. Shiraev T and Barclav G. Evidence based exercise- Clinical benefits of high intensity interval training. *Aust Fam Physician* 2012; 41 (12): 960-962.
17. Wisloff U, Stovlen A, Loennechen JP, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients. *Circulation* 2007; 115: 3086-3094.
18. Vogiatzis I, Gerasimos Terzis, Serafeim Nanas, *et al*. Skeletal muscle adaptations to interval training in patients with advanced COPD. *Chest* 2005; 128: 3838-3845.
19. Vogiatzis I, Nanas S, Kastanakis E, et al. Dynamic hyperinflation and tolerance to interval exercise in patients with advanced COPD. *Eur Respir J* 2004; 24: 385–390.
20. Kortianou EA, Nasis IG, Spetsioti ST, et al. Effectiveness of interval exercise training in patients with COPD. *Cardiopulm Phys Ther J* 2010; 21: 12–19.
21. Beauchamp M. A, Nonoyama M., Goldstein R. S., et al. Interval versus continuous training in individuals with chronic obstructive pulmonary disease- a systematic review. *Thorax* 2010; 65: 157-164.
22. Gloeckl R, Halle M, Kenn K. Interval versus continuous training in lung transplant candidates: a randomized trial. *J Heart Lung Transplant* 2012; 31: 934–941.
23. Nikoletou D, Lech C. Y., MacNaughton I.S, Chis-Ster I., Chua F., Aul R., Jones P.. High intensity interval versus moderate intensity continuous training in pulmonary rehabilitation for patients with interstitial lung disease. - American Thoracic Society Conference- B109. HIGHLIGHTS AND ADVANCES IN PULMONARY REHABILITATION. May 2016, A4520-A4520 San Francisco, USA.
24. Manali, E.D., Lyberopoulos, P., Triantafillidou, C. *et al.* MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study. *BMC Pulm Med* **10**, 32 (2010). https://doi.org/10.1186/1471-2466-10-32
25. Borg G: Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med. 1970, 2: 92-98.
26. Borg GA: Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982, 14: 377-381
27. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002; 166: 111–17.
28. Yorke J, Jones P, Swigris J J. Development and validity testing of an IPF-specific version of the St George’s Respiratory questionnaire. *Thorax* 2010; 65: 921-926.
29. Zigmond AS and Snaith RP: The Hospital Anxiety And Depression Scale. *Acta Psychiatr Scand* 1983, 67:361-70
30. PA Harris, R Taylor, BL Minor, V Elliott, M Fernandez, L O’Neal, L McLeod, G Delacqua, F Delacqua, J Kirby, SN Duda, REDCap Consortium, **The REDCap consortium: Building an international community of software partners**. J Biomed Inform. 2019 May 9 [doi: 10.1016/j.jbi.2019.103208]
31. Resources for pilot and feasibility studies. Available from: <https://pilotandfeasibilitystudies.qmul.ac.uk/> resources/.
32. Holland AE, Hill CJ, Connon M, *et al*. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. *Thorax* 2008; 63: 549-554.
33. Perez-Bogerd S., Wuyts W, Barbier V, Demeyer H, Van Muylem A, Janssens W, Troosters T. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. *Respiratory Research* 2018; 19 (1): 182.
34. Bell EC, Cox NS, Goh N, et al. Oxygen therapy for interstitial lung disease: a systematic review. *Eur Respir Rev* 2017: 26: 160080 [https://doi.org/10.1183/16000617.0080-2016]
35. Sterne J A C, White I R, Carlin J B, Spratt M, Royston P, Kenward M G et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ* 2009; 338: b2393 doi: 10.1136/bmj.b2393.
36. Holland AE, Hill CJ, Connon M, *et al*. Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. *Respir Med* 2009; 103:1430-5.
37. du Bois RM, Weycker D, Albera C, et al. Six-minute walk test in idiopathic pulmonary fibrosis; test validation and minimal clinically important difference. *Am J Respir Crit Care Med* 2011; 183: 1231-1237.
38. Tonelli R, Cocconcelli E, Lanini B, Romagnoli I et al. Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology; a multicentre prospective study. *BMC Pulmonary Medicine* 2017; 17: 1-9.
39. Nishiyama O, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S, Nishimura K, Taniguchi H. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. *Respirology* 2008;13:394–9.
40. Vainshelboim B, Oliveira J, Yehoshua L, Weiss I, Fox BD, Fruchter O, Kramer MR. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. *Respiration*. 2014;88:378–88.
41. Ferreira A, Garvey C, Connors GL, Hilling L, Rigler J, Farrell S, Cayou C, Shariat C, Collard HR. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. *Chest* 2009;135:442–7.
42. Jackson RM, Gomez-Marin OW, Ramos CF, Sol CM, Cohen MI, Gaunaurd IA, Cahalin LP, Cardenas DD. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. *Lung* 2014;192:367–76.
43. Ryerson CJ, Cayou C, Topp F, et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. *Respir Med* 2014;108:203–10.
44. Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. *Eur Respir J* 2010; 36(1): 81–88.
45. Swallow EB, Reyes D, Hopkinson NS, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. *Thorax* 2007; 62(2): 115–120.
46. Mendes P, Wicherson L, Helm D, et al. Skeletal muscle atrophy in advanced interstitial lung disease. *Respirology* 2015; 20: 953-959.
47. Mendoza L, Gogali A, Shrikrishna D, Cavada G, et al. Quadriceps strength and endurance in fibrotic idiopathic interstitial pneumonia. *Respirology* 2014; 19: 138-143.
48. de Troyer A, Yernault JC, Inspiratory muscle force in normal subjects and patients with interstitial lung disease. *Thorax* 1980; 35: 92-100.
49. Roberts C, Torgerson D J. Baseline imbalance in randomised controlled trials. *BMJ* 1999; 319: 185.
50. Tonelli R, Cocconcelli E, Lanini B, et al. Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology; a multicentre prospective study. *BMC Pulmonary Medicine* 2017; 17: 130-139.
51. Dowman LM, McDonald CF, Bozinovski S, Vlahos R, Gillies R, Pouniotis D, Hill CJ, Goh NSL, Holland AE. Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia. *Respirology* 2017; 22: 957-964.
52. Johnson-Warrington V, Williams J, Bankart J, Steiner M, Morgan M, Singh S. Pulmonary rehabilitation and Interstitial lung disease: Aiding the referral decision. *J Cardiopulm Rehabil Prev*2013; 33 (3): 189-195.